Phase 3RecruitingPriority 1 · Highest priorityNCT06776952
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Plain-language summary
This Phase 3 trial is comparing XNW5004 ; Chidamide placebo and XNW5004 placebo; Chidamide against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Days to 70 Days years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XNW5004 ; Chidamide placebo (DRUG): XNW5004 + Chidamide placebo | XNW5004 placebo; Chidamide (DRUG): XNW5004 placebo + Chidamide
- Drugs / treatments
- XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details